PSA-006

  • STATUS
    Recruiting
Updated on 23 November 2020

Summary

PSA-006

Description

A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects with Active Psoriatic Arthritis

IRB Number: 013-194

Location: Baylor Research Institute

Facility Name: Arthritis Care and Research Institute

Facility Street Address: 9900 N. Central Expy Suite 550
City: Dallas, TX Zip Code: 75231

Lead Principal Investigator: Dr. John Cush

Details
Clinical Study IdentifierTX138972
Last Modified on23 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 0 yrs?
Gender: Male or Female
Age 18 or older
Diagnosis of Psoriatic Arthritis greater than or equal to 3 months
Disease activity defined by = 3 tender joint out of 68 & = 3 swollen joints out of 66
Must not have taken a TNF blocker medication (such as Enbrel, Humira, Cimzia, Simponi, etc.)
Taking 1 DMARD only
If taking oral corticosteroids, must be on a stable dose of less than or equal to 10mg per day for at least 30 days

Exclusion Criteria

Prior treatment of more than one DMARD (such as Methotrexate, Sulfazalazine, Leflunomide, Cyclosporine, etc.)
Malignancy or a history of malignancy
Previous treatment with biologic agents for rheumatic diseases (such as Enbrel, Humira, Cimzia, Simponi, etc.)
Prior history of a rheumatic autoimmune disease such as SLE (lupus), Rheumatoid Arthritis, Ankylosing Spondylitis, Lyme disease, Fibromyalgia, etc
Other exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note